J&J to supply Europe with 200 million doses of COVID-19 vaccine
J&J has agreed that it will supply the EU with 200 million doses of its COVID-19 vaccine candidate following regulatory approval.
List view / Grid view
J&J has agreed that it will supply the EU with 200 million doses of its COVID-19 vaccine candidate following regulatory approval.
The UK government will receive one million rapid COVID-19 antibody tests from Abingdon Health that provide results in 20 minutes.
Eli Lilly has given an update on its neutralising antibody programmes, including its combination therapy in patients with COVID-19.
Christoph Krähenbühl outlines five considerations for virtual pharmaceutical companies when launching a new drug product.
A new report has found that three quarters of dose manufacturing facilities acquired by dedicated CMOs in 2019 were in Europe.
5 October 2020 | By Merck KGaA
This on-demand webinar provides an overview of a holistic approach to achieve compliance with good manufacturing practice (GMP) requirements for environmental monitoring (EM) in aseptic manufacturing areas, such as ISO 5 cleanrooms in traditional setup, RABS or isolators.
A new opinion piece from Watson-Marlow Fluid Technology Group has been launched.
Watson-Marlow Fluid Technology Group discusses how the biopharma community is coming together to solve the global vaccine development challenge.
US outsourcing organisation GRAM is set to undertake the aseptic fill and finish manufacture of J&J's COVID-19 vaccine candidate.
Due to the demand caused by the COVID-19 pandemic, the UK government has said British manufacturers will produce the majority of PPE by the end of the year.
A report has said that the highly potent compound market will grow to be worth $32,200 million by the end of 2026.
The ABPI and EFPIA have both emphasised the need for trade talks to mitigate medicine supply chain disruptions following Brexit.
Researchers have shown that sublimation tests should be conducted if new components are added to the freeze-drying process of HPAPIs.
A new report has said that a quarter of drugs globally are based on highly potent active pharmaceutical ingredients.
As the COVID-19 pandemic and the search for an effective preventative vaccine continues, the Serum Institute of India has entered into manufacturing agreements with both Novavax and Codagenix to help supply their experimental COVID-19 vaccine candidates.